Veru (NASDAQ:VERU) Issues Quarterly Earnings Results

Veru (NASDAQ:VERU – Get Rating) released its quarterly earnings data on Thursday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02), MarketWatch Earnings reports. Veru had a negative net margin of 26.68% and a negative return on equity of 10.62%. During the same quarter in the prior year, the business posted ($0.04) earnings per share.

Shares of NASDAQ:VERU opened at $13.00 on Friday. Veru has a 1-year low of $4.34 and a 1-year high of $17.50. The business has a fifty day moving average price of $8.17 and a 200-day moving average price of $7.06. The company has a market capitalization of $1.04 billion, a PE ratio of -38.23 and a beta of -0.57.

Large investors have recently modified their holdings of the company. Bank of America Corp DE boosted its position in shares of Veru by 163.7% during the fourth quarter. Bank of America Corp DE now owns 48,680 shares of the company’s stock valued at $286,000 after buying an additional 30,218 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Veru by 739.8% during the fourth quarter. Wells Fargo & Company MN now owns 45,347 shares of the company’s stock valued at $268,000 after buying an additional 39,947 shares during the last quarter. Credit Suisse AG boosted its position in shares of Veru by 22.7% during the fourth quarter. Credit Suisse AG now owns 44,657 shares of the company’s stock valued at $262,000 after buying an additional 8,253 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Veru during the fourth quarter valued at $198,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Veru during the third quarter valued at $169,000. Hedge funds and other institutional investors own 29.11% of the company’s stock.

A number of equities analysts have issued reports on the stock. HC Wainwright lifted their price objective on shares of Veru from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, April 12th. Oppenheimer boosted their price target on shares of Veru from $25.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday, April 12th. Jefferies Financial Group boosted their price objective on Veru from $33.00 to $55.00 in a research note on Friday. Zacks Investment Research cut Veru from a “buy” rating to a “hold” rating in a research report on Thursday, April 21st. Finally, TheStreet upgraded Veru from a “d+” rating to a “c” rating in a research report on Friday, April 29th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $32.75.

Veru Company Profile (Get Rating)

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

Read More